• Brefeldin A: Bridging ER Stress Mechanisms to Cancer Innovat

  2026-05-09

  This thought-leadership article explores the mechanistic and translational power of Brefeldin A (BFA) as an ER stress inducer and apoptosis enhancer in cancer models. By integrating new insights on protein quality control, E3 ligase function in ER stress, and workflow optimization, it offers strategic guidance for researchers leveraging BFA in advanced disease modeling. The discussion connects molecular findings to practical assay design, competitive positioning, and future-ready translational strategies.

• Z-VAD-FMK: Expanding the Frontiers of Apoptosis Inhibition R

  2026-05-08

  Explore how Z-VAD-FMK, a robust pan-caspase inhibitor, is driving innovation in apoptosis inhibition and immune evasion studies. This article uniquely bridges assay design with new host-pathogen insights, offering advanced perspectives beyond standard protocols.

• ATG9A and PTOV1: Novel 14-3-3 Interactors in Cancer Regulati

  2026-05-08

  This study identifies ATG9A and PTOV1 as previously unknown 14-3-3 binding proteins, unveiling their mechanistic roles in autophagy and oncogenic signaling. The work advances our understanding of cancer-related cellular pathways and highlights new molecular targets for therapeutic research.

• Poria cocos Polysaccharides Mitigate ALD via NRF2-Mediated F

  2026-05-07

  This study demonstrates that Poria cocos polysaccharides (PCP) ameliorate alcoholic liver disease (ALD) in rats by interfering with ferroptosis through NRF2 pathway regulation. The results provide mechanistic insight into the interplay between oxidative stress, inflammation, and iron metabolism in ALD, highlighting NRF2 as a therapeutic target.

• Dual Inhibition of FUBP1 and Topoisomerase I by SN-38 in Can

  2026-05-07

  The referenced study reveals that camptothecin and its analog SN-38 not only inhibit topoisomerase I but also disrupt binding of the oncoprotein FUBP1 to its DNA target, FUSE. This dual mechanism expands the rationale for using SN-38 and related inhibitors in advanced cancer research, with direct implications for targeting transcriptional regulation in tumor cells.

• Safe DNA Gel Stain: Enhanced DNA and RNA Gel Stain Workflows

  2026-05-06

  Safe DNA Gel Stain empowers researchers to visualize nucleic acids with heightened sensitivity and safety, outperforming traditional stains like ethidium bromide. Discover how its blue-light compatibility and low mutagenicity streamline molecular biology protocols and enable safer, higher-fidelity cloning experiments.

• Pifithrin-α (PFTα): Precision p53 Inhibition Beyond Neuropro

  2026-05-06

  Discover how Pifithrin-α, a potent p53 inhibitor, enables advanced control of p53-dependent apoptosis and ferroptosis. This article uniquely explores protocol parameters and translational insights for mitigating neurotoxicity and optimizing experimental design.

• MLN8237 (Alisertib): Precision Aurora A Inhibition in Cancer

  2026-05-05

  MLN8237 (Alisertib) from APExBIO empowers researchers to dissect Aurora A kinase’s role in oncogenesis and trained immunity via robust, data-driven workflows. Its high specificity, ease of integration in both in vitro and in vivo protocols, and proven apoptosis induction make it indispensable for translational cancer biology and preclinical modeling.

• Tβ4 Drives Angiogenesis in CLI via Notch/NF-κB Pathway Modul

  2026-05-05

  Lv et al. elucidate how thymosin-β4 (Tβ4) enhances angiogenesis in a critical limb ischemia (CLI) mouse model by activating Notch and NF-κB pathways. Their mechanistic findings, supported by functional and molecular assays, suggest new therapeutic angles for ischemic vascular disease and highlight the utility of pathway-specific inhibitors.

• Protease Inhibitor Cocktail: Enhancing Protein Stability in

  2026-05-04

  Unlock high-fidelity protein extraction from cell and tissue lysates with the APExBIO Protease Inhibitor Cocktail (100X H₂O, EDTA Plus). This robust, ready-to-use solution ensures proteome integrity during advanced lipid droplet and metabolic assays, supporting reliable quantification of labile complexes in cutting-edge workflows.

• Quercetin Protects Cataract Lenses via Hippo Pathway Modulat

  2026-05-04

  This study elucidates how quercetin mitigates cataract pathology by suppressing the Hippo signaling pathway, promoting lens epithelial cell survival and reducing oxidative damage. The findings clarify molecular mechanisms underlying quercetin's protective effects and highlight new directions for non-surgical cataract interventions.

• Polyethylenimine Linear (PEI), MW 40,000: Protocol Precision

  2026-05-03

  Explore how Polyethylenimine Linear (PEI), MW 40,000 enables precise, high-efficiency DNA transfection in in vitro research. This article uniquely dissects protocol optimization and the scientific rationale behind PEI performance, offering insights beyond typical reagent guides.

• Firefly Luciferase mRNA (ARCA, 5mCTP, ΨUTP): Unraveling Stab

  2026-05-02

  Explore the advanced science behind Firefly Luciferase mRNA (ARCA, 5mCTP, ΨUTP) in gene expression and in vivo imaging. This in-depth article reveals how buffer formulation and nucleotide modifications shape assay reliability, offering new insights beyond standard reviews.

• Protease Inhibitor Cocktail EDTA-Free: Safeguarding Lysosoma

  2026-05-01

  Explore the critical role of Protease Inhibitor Cocktail EDTA-Free in preserving protein integrity during extraction and advanced assays. This article uniquely connects lysosomal repair mechanisms with practical proteomics, offering new scientific insights beyond standard workflow recommendations.

• SN-38 and Camptothecin Block FUBP1–FUSE Binding in Cancer Ce

  2026-05-01

  This study uncovers a novel mechanism by which camptothecin and its analog SN-38—best known as DNA topoisomerase I inhibitors—directly inhibit the binding of the oncoprotein FUBP1 to its DNA target, FUSE, in tumor cells. These findings broaden our understanding of SN-38's action in advanced cancer models and suggest dual-pathway targeting as a promising strategy in colon and hepatocellular carcinoma research.

16285 records 1/1086 page Next 12345 下5页 Last page